Open an account

Nabriva Therapeutics

NBRVF · OTC

$0.0001+$0.00 (+0.00%)TodayMarket closed ·
No price history for this range.

About NBRVF

Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the commercialization and development of novel anti-infective agents to treat infections. The firm's product, XENLETA (lefamulin injection, lefamulin tablets), is the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP). XENLETA is designed to inhibit the synthesis of a specific protein on the bacterial ribosome, required for bacterial growth, by binding with high affinity and specificity at molecular targets different from those of other available antibiotic classes, causing cell death.

Employees
39
Headquarters
DUBLIN
Listed
Sep 18, 2015
Sector
Health Care
Industry
Pharmaceuticals
Website
nabriva.com

NBRVF key statistics

Market cap
323
Price-earnings ratio
-0.00
Dividend yield
—
Average volume
530
Volume
12
Open price
$0.0001
High today
$0.0001
Low today
$0.0001
52 Week high
$0.0002
52 Week low
$0.00

Nabriva Therapeutics (NBRVF) at a glance

As of Jun 15, 2026, Nabriva Therapeutics (NBRVF) shares are priced at $0.0001, giving the company a market cap of 323 and a price-to-earnings ratio of 0.00.

Volume so far is 12 shares, below the average of 530 shares a day.

Over the past year Nabriva Therapeutics has ranged from $0.00 to $0.0002, and now sits 50% of the way up that range.

Nabriva Therapeutics met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q3 FY22 it reported -$4.21 per share against an estimate of -$4.15.

NBRVF earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 36.6% on average.

  1. Q4 FY20: reported -$27.75 per share against an estimate of -$24.46
  2. Q1 FY21: reported -$13.25 per share against an estimate of -$17.25
  3. Q2 FY21: reported -$7.25 per share against an estimate of -$8.93
  4. Q3 FY21: reported -$0.525 per share against an estimate of -$6.31
  5. Q4 FY21: reported -$6.00 per share against an estimate of -$4.89
  6. Q1 FY22: reported -$5.00 per share against an estimate of -$4.89
  7. Q2 FY22: reported -$4.50 per share against an estimate of -$5.15
  8. Q3 FY22: reported -$4.21 per share against an estimate of -$4.15

Similar companies

Companies in the same industry as Nabriva Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.